StreetInsider.com News Articles

Form 8-K CRESCENT BIOPHARMA, INC. For: Jun 02

Wed, 03 Jun 2026 09:03:00 -0400

si-local-file:///var/storage/secattach/20260603/26596512.html

Form 8-K CRESCENT BIOPHARMA, INC. For: Jun 02

Wed, 03 Jun 2026 09:03:00 -0400

si-local-file:///var/storage/secattach/20260603/26596512.html

Crescent Biopharma to Present at June Investor Conferences

Tue, 02 Jun 2026 16:15:00 -0400

WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in June:

2026 Jefferies Global Healthcare Conference, fireside chat on Wednesday, June 3, 2026 at 4:20 p.m. ET in New York
Goldman Sachs 47^th Annual Global Healthcare Conference, fireside chat on Monday, June 8, 2026 at 8:40 a.m. ET in Miami

A live webcast

Crescent Biopharma to Present at June Investor Conferences

Tue, 02 Jun 2026 16:15:00 -0400

2026 Jefferies Global Healthcare Conference, fireside chat on Wednesday, June 3, 2026 at 4:20 p.m. ET in New York
Goldman Sachs 47^th Annual Global Healthcare Conference, fireside chat on Monday, June 8, 2026 at 8:40 a.m. ET in Miami

A live webcast

H.C. Wainwright Downgrades Crescent Biopharma Inc (CBIO) to Neutral

Mon, 01 Jun 2026 06:41:09 -0400

(Updated - June 1, 2026 6:41 AM EDT)

H.C. Wainwright analyst Mitchell S. Kapoor downgraded Crescent Biopharma Inc (NASDAQ: CBIO) from Buy to Neutral.

The analyst comments "Downgrading to Neutral: ivo-copycat thesis is less compelling after competitive sac-TMT data—see data table below. Our prior rating rested on CR-001 as a fast follower to Summit (SMMT; Neutral) and Akeso’s ivonescimab, with similar PD-1 x VEGF biology and cooperative pharmacology. That thesis was predicated on ivo being a potential Keytruda displacer. It is harder to support the same valuation credit for CR-001 after Merck & Co. (MRK; not rated) and Kelun’s sacituzumab tirumotecan (sac-TMT)

H.C. Wainwright Downgrades Crescent Biopharma Inc (CBIO) to Neutral

Mon, 01 Jun 2026 06:41:09 -0400

(Updated - June 1, 2026 6:41 AM EDT)

H.C. Wainwright analyst Mitchell S. Kapoor downgraded Crescent Biopharma Inc (NASDAQ: CBIO) from Buy to Neutral.

Crescent Biopharma Announces Grants of Inducement Awards

Fri, 29 May 2026 16:15:00 -0400

WALTHAM, Mass., May 29, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 16,950 shares of the Company’s ordinary shares to two non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the “Inducement Plan”). The options were approved on May 28, 2026 and were

Crescent Biopharma Announces Grants of Inducement Awards

Fri, 29 May 2026 16:15:00 -0400

Crescent Biopharma to present CR-001 trial data at ASCO 2026

Thu, 21 May 2026 17:36:24 -0400

Crescent Biopharma Inc. (NASDAQ: CBIO) announced it will present a trial in progress poster for its ASCEND study of CR-001 at the American Society of Clinical Oncology Annual Meeting from May 29 to June 2 in Chicago.

CR-001 is a PD-1 x VEGF bispecific antibody being evaluated in the ASCEND Phase 1/2 global clinical trial for multiple solid tumor types, including non-small cell lung cancer and gastrointestinal and gynecological cancers. The study is enrolling up to 290 patients across dose-escalation, backfill and dose-optimization cohorts in the United States, Europe and Asia Pacific.

The trial's primary objectives focus on evaluating safety and tolerability

Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

Thu, 21 May 2026 17:30:00 -0400

ASCEND Phase 1/2 global clinical trial evaluating CR-001 in multiple solid tumor types, including NSCLC, gastrointestinal and gynecological cancers in first-line and previously treated patients

Multiple CR-001 clinical data readouts anticipated beginning in Q1 2027

Waltham, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced a trial in progress poster of the ASCEND study of CR-001, a PD-1 x VEGF bispecific antibody, will be presented

Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

Thu, 21 May 2026 17:30:00 -0400

ASCEND Phase 1/2 global clinical trial evaluating CR-001 in multiple solid tumor types, including NSCLC, gastrointestinal and gynecological cancers in first-line and previously treated patients

Multiple CR-001 clinical data readouts anticipated beginning in Q1 2027

Form SCHEDULE 13G/A CRESCENT BIOPHARMA, INC. Filed by: TANG CAPITAL MANAGEMENT LLC

Fri, 15 May 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260515/26505855.html

Form SCHEDULE 13G/A CRESCENT BIOPHARMA, INC. Filed by: TANG CAPITAL MANAGEMENT LLC

Fri, 15 May 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260515/26505855.html

Form SCHEDULE 13G CRESCENT BIOPHARMA, INC. Filed by: BALYASNY ASSET MANAGEMENT L.P.

Fri, 15 May 2026 06:31:00 -0400

si-local-file:///var/storage/secattach/20260515/26498920.html

Form SCHEDULE 13G CRESCENT BIOPHARMA, INC. Filed by: BALYASNY ASSET MANAGEMENT L.P.

Fri, 15 May 2026 06:31:00 -0400

si-local-file:///var/storage/secattach/20260515/26498920.html

Crescent Biopharma Announces Grants of Inducement Awards

Tue, 12 May 2026 16:30:00 -0400

WALTHAM, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 129,075 shares of the Company’s ordinary shares to five non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the “Inducement Plan”). The options were approved on May 11, 2026 and

Crescent Biopharma Announces Grants of Inducement Awards

Tue, 12 May 2026 16:30:00 -0400

Crescent Biopharma to Present at May Investor Conferences

Wed, 06 May 2026 07:30:00 -0400

WALTHAM, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in May:

BofA Securities 2026 Healthcare Conference, fireside chat on Wednesday, May 13, 2026 at 4:20 p.m. PT (7:20 p.m. ET) in Las Vegas
2026 Stifel Virtual Targeted Oncology Forum, virtual fireside chat on Wednesday, May 20, 2026 at 2:30 p.m. ET
TD Cowen 7th

Crescent Biopharma to Present at May Investor Conferences

Wed, 06 May 2026 07:30:00 -0400

WALTHAM, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in May:

BofA Securities 2026 Healthcare Conference, fireside chat on Wednesday, May 13, 2026 at 4:20 p.m. PT (7:20 p.m. ET) in Las Vegas
2026 Stifel Virtual Targeted Oncology Forum, virtual fireside chat on Wednesday, May 20, 2026 at 2:30 p.m. ET
TD Cowen 7th

Crescent Biopharma to Present at May Investor Conferences

Wed, 06 May 2026 07:30:00 -0400

WALTHAM, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in May:

BofA Securities 2026 Healthcare Conference, fireside chat on Wednesday, May 13, 2026 at 4:20 p.m. PT (7:20 p.m. ET) in Las Vegas
2026 Stifel Virtual Targeted Oncology Forum, virtual fireside chat on Wednesday, May 20, 2026 at 2:30 p.m. ET
TD Cowen 7th

Crescent Biopharma to Present at May Investor Conferences

Wed, 06 May 2026 07:30:00 -0400

WALTHAM, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in May:

BofA Securities 2026 Healthcare Conference, fireside chat on Wednesday, May 13, 2026 at 4:20 p.m. PT (7:20 p.m. ET) in Las Vegas
2026 Stifel Virtual Targeted Oncology Forum, virtual fireside chat on Wednesday, May 20, 2026 at 2:30 p.m. ET
TD Cowen 7th

Crescent Biopharma to Present at May Investor Conferences

Wed, 06 May 2026 07:30:00 -0400

WALTHAM, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in May:

BofA Securities 2026 Healthcare Conference, fireside chat on Wednesday, May 13, 2026 at 4:20 p.m. PT (7:20 p.m. ET) in Las Vegas
2026 Stifel Virtual Targeted Oncology Forum, virtual fireside chat on Wednesday, May 20, 2026 at 2:30 p.m. ET
TD Cowen 7th

Crescent Biopharma to Present at May Investor Conferences

Wed, 06 May 2026 07:30:00 -0400

WALTHAM, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in May:

BofA Securities 2026 Healthcare Conference, fireside chat on Wednesday, May 13, 2026 at 4:20 p.m. PT (7:20 p.m. ET) in Las Vegas
2026 Stifel Virtual Targeted Oncology Forum, virtual fireside chat on Wednesday, May 20, 2026 at 2:30 p.m. ET
TD Cowen 7th

Crescent Biopharma to Present at May Investor Conferences

Wed, 06 May 2026 07:30:00 -0400

WALTHAM, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in May:

BofA Securities 2026 Healthcare Conference, fireside chat on Wednesday, May 13, 2026 at 4:20 p.m. PT (7:20 p.m. ET) in Las Vegas
2026 Stifel Virtual Targeted Oncology Forum, virtual fireside chat on Wednesday, May 20, 2026 at 2:30 p.m. ET
TD Cowen 7th

Crescent Biopharma to Present at May Investor Conferences

Wed, 06 May 2026 07:30:00 -0400

WALTHAM, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in May:

BofA Securities 2026 Healthcare Conference, fireside chat on Wednesday, May 13, 2026 at 4:20 p.m. PT (7:20 p.m. ET) in Las Vegas
2026 Stifel Virtual Targeted Oncology Forum, virtual fireside chat on Wednesday, May 20, 2026 at 2:30 p.m. ET
TD Cowen 7th